FNCH vs. SKYE, JMAC, TNYA, CUE, VOR, SLS, ADVM, HLVX, JSPR, and ANRO
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Skye Bioscience (SKYE), Maxpro Capital Acquisition (JMAC), Tenaya Therapeutics (TNYA), Cue Biopharma (CUE), Vor Biopharma (VOR), SELLAS Life Sciences Group (SLS), Adverum Biotechnologies (ADVM), HilleVax (HLVX), Jasper Therapeutics (JSPR), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry.
Finch Therapeutics Group vs.
Finch Therapeutics Group (NASDAQ:FNCH) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
In the previous week, Skye Bioscience had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Skye Bioscience and 1 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score.
Finch Therapeutics Group has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.
Skye Bioscience's return on equity of -45.78% beat Finch Therapeutics Group's return on equity.
Skye Bioscience received 1 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 100.00% of users gave Skye Bioscience an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
Skye Bioscience has lower revenue, but higher earnings than Finch Therapeutics Group.
21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Skye Bioscience has a consensus target price of $18.67, suggesting a potential upside of 526.40%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Finch Therapeutics Group.
Summary
Skye Bioscience beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
This page (NASDAQ:FNCH) was last updated on 2/22/2025 by MarketBeat.com Staff
Free FNCH Stock Alerts